ATRA - CIK 0001604464
Atara Biotherapeutics, Inc. trades as ATRA. In its fiscal 2025 annual report the company posted revenue of $120.77M, down 6.3% from the prior year and net income of $32.69M. This page tracks Atara Biotherapeutics, Inc. through 999 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -359.1% to 27.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-18 |
| SCHEDULE 13D/A | - | 2026-05-14 |
| SCHEDULE 13G | - | 2026-05-13 |
| Prospectus supplement | 424B5 | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-12 |
The largest companies sharing Atara Biotherapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Atara Biotherapeutics, Inc. reported revenue of $120.77M for fiscal year 2025, a decrease of 6.3% year over year.
Yes. Atara Biotherapeutics, Inc. reported net income of $32.69M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.